Search Results

You are looking at 1 - 10 of 290 items for :

  • "bevacizumab" x
Clear All
Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer . Nat Med 2004 ; 10 : 145 – 147 . 11. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for

Full access

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan and Steven Brem

vasculature improves glioblastoma response to radiation therapy, 2 probably through increasing oxygen delivery and allowing radiation to work better in a normoxic rather than a hypoxic tumor microenvironment. 2 , 3 Bevacizumab, a monoclonal antibody against

Full access

Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson and John P. Kirkpatrick

bevacizumab, followed by temozolomide, bevacizumab, and irinotecan (CPT-11). Four weeks after surgery, he began radiotherapy (volumetric modulated arc therapy), receiving 50.4 Gy to the left frontoparietal region with a 9-Gy boost to the tumor bed over 6

Full access

Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer and Anil Vachani

patients lack a targetable mutation, carboplatin/pemetrexed alone or with the antiangiogenic monoclonal antibody bevacizumab remains a relevant systemic regimen. Bevacizumab was initially approved for nonsquamous NSCLC in 2006 based on results of the

Full access

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock and Kenneth R. Hess

patients with small cell lung cancer treated with single-agent bendamustine 5 or bendamustine combined with carboplatin, 4 the overall response rates were 29% and 73%, respectively. Bevacizumab is a recombinant humanized antibody directed against

Full access

Catherine Larkin

The FDA's approval of the cancer drug bevacizumab (Avastin; Roche/Genentech) in February 2004 validated a 30-year-old theory, championed by Judah Folkman, MD, of Harvard, that tumors can be stopped by choking off their blood supply. Enthusiasm for

Full access

Lyndsay J. Willmott, Daniele A. Sumner and Bradley J. Monk

histologic microvessel density counts. Hawighorst et al. 18 evaluated primary tumors treated with radical hysterectomy, and found that the exchange rate constant was a significant predictor of poor patient survival. VEGF Targeted Therapy Bevacizumab

Full access

L. Burt Nabors

sequelae result in a marked deterioration in neurologic function which, in turn, results in a diminished quality of life in an already vulnerable patient population. The initial FDA approval for the use of bevacizumab in GBM, and its resulting inclusion

Full access

Joseph Rosales and Lucille A. Leong

): 3525 . 15 Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, Fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 – 2342 . 16 Giantonio BJ Catalano PJ Meropol NJ . High

Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner and Henry S. Friedman

radiographic responses and improved progression-free survival with bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), 7 among patients with recurrent malignant glioma. 8 – 11 However, initial enthusiasm has been